2023
Relative Burden of Cancer and Noncancer Mortality Among Long-Term Survivors of Breast, Prostate, and Colorectal Cancer in the US
Kc M, Fan J, Hyslop T, Hassan S, Cecchini M, Wang S, Silber A, Leapman M, Leeds I, Wheeler S, Spees L, Gross C, Lustberg M, Greenup R, Justice A, Oeffinger K, Dinan M. Relative Burden of Cancer and Noncancer Mortality Among Long-Term Survivors of Breast, Prostate, and Colorectal Cancer in the US. JAMA Network Open 2023, 6: e2323115. PMID: 37436746, PMCID: PMC10339147, DOI: 10.1001/jamanetworkopen.2023.23115.Peer-Reviewed Original ResearchConceptsLong-term survivorsCancer-specific mortalityColorectal cancerCancer cohortReceptor statusInitial diagnosisGleason scoreProstate cancerBreast cancerLong-term adult survivorsMedian cancer-specific survivalEnd Results cancer registryProstate-specific antigen levelRectal cancer cohortCancer-specific survivalStage III diseaseYear of diagnosisProgesterone receptor statusEstrogen receptor statusProportion of deathsSurvival time ratioEarly-stage cancerNononcologic outcomesIndex cancerLocalized disease
2021
Considering lead-time bias in evaluating the effectiveness of lung cancer screening with real-world data
Yang SC, Wang JD, Wang SY. Considering lead-time bias in evaluating the effectiveness of lung cancer screening with real-world data. Scientific Reports 2021, 11: 12180. PMID: 34108586, PMCID: PMC8190256, DOI: 10.1038/s41598-021-91852-6.Peer-Reviewed Original ResearchConceptsLead-time biasNational Lung Screening TrialStage shiftStage IALife expectancyCancer patientsLung cancerCalendar yearNationwide cancer registryBenefits of screeningLung cancer patientsReal-world studyLung cancer diagnosisMean life expectancyTomography screeningCancer RegistryLE gainsCancer screeningEarly diagnosisScreening TrialGeneral populationSame pathologyYounger agePathologyCancer diagnosisCost-Effectiveness of Adjuvant Treatment for Ductal Carcinoma In Situ
Gupta A, Jhawar SR, Sayan M, Yehia ZA, Haffty BG, Yu JB, Wang SY. Cost-Effectiveness of Adjuvant Treatment for Ductal Carcinoma In Situ. Journal Of Clinical Oncology 2021, 39: 2386-2396. PMID: 34019456, PMCID: PMC10166354, DOI: 10.1200/jco.21.00831.Peer-Reviewed Original ResearchConceptsAromatase inhibitorsTreatment strategiesRadiation treatmentDuctal carcinomaAge 40Risk reductionAdjuvant treatment strategiesGood-risk patientsLarge randomized trialsAdverse event ratesOptimal treatment strategyRelative risk reductionCohort of womenBreast cancer casesLow-value careQuality of lifeCost-effectiveness analysisBase-case resultsHormonal therapyAdjuvant treatmentMost patientsPatient ageSecondary malignanciesRandomized trialsRecurrence rate
2020
Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)–Positive Breast Cancer
Kunst N, Wang SY, Hood A, Mougalian SS, DiGiovanna MP, Adelson K, Pusztai L. Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)–Positive Breast Cancer. JAMA Network Open 2020, 3: e2027074. PMID: 33226431, PMCID: PMC7684449, DOI: 10.1001/jamanetworkopen.2020.27074.Peer-Reviewed Original ResearchMeSH KeywordsAdo-Trastuzumab EmtansineAdultAgedAnthracyclinesAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalAntineoplastic Agents, PhytogenicBreast NeoplasmsCase-Control StudiesCost-Benefit AnalysisCross-Linking ReagentsDrug Therapy, CombinationFemaleHumansImmunosuppressive AgentsMiddle AgedNeoadjuvant TherapyPaclitaxelQuality-Adjusted Life YearsReceptor, ErbB-2TrastuzumabTubulin ModulatorsUnited StatesConceptsErbB2-positive breast cancerAdjuvant treatment strategiesAdjuvant T-DM1Pathologic complete responseT-DM1Treatment strategiesBreast cancerKATHERINE trialResidual diseaseNeoadjuvant regimenHigher health benefitsHealth care payer perspectiveAdjuvant trastuzumab emtansineAnthracycline/cyclophosphamideDifferent adjuvant therapiesFlatiron Health databaseIncremental cost-effectiveness ratioNeoadjuvant treatment optionsHealth benefitsPositive breast cancerCare payer perspectiveCost-effectiveness ratioBase-case analysisDecision analytic modelH. PatientsRacial and Ethnic Disparities in Population-Level Covid-19 Mortality
Gross CP, Essien UR, Pasha S, Gross JR, Wang SY, Nunez-Smith M. Racial and Ethnic Disparities in Population-Level Covid-19 Mortality. Journal Of General Internal Medicine 2020, 35: 3097-3099. PMID: 32754782, PMCID: PMC7402388, DOI: 10.1007/s11606-020-06081-w.Peer-Reviewed Original ResearchChanges in community mental health services availability and suicide mortality in the US: a retrospective study
Hung P, Busch SH, Shih YW, McGregor AJ, Wang S. Changes in community mental health services availability and suicide mortality in the US: a retrospective study. BMC Psychiatry 2020, 20: 188. PMID: 32334552, PMCID: PMC7183673, DOI: 10.1186/s12888-020-02607-y.Peer-Reviewed Original ResearchConceptsSuicide mortalityNational Mental Health Services SurveySuicide deathsMental health service availabilityHealth service availabilityMental health servicesMental health careHealth Services SurveySuicide prevention effortsMethodsRetrospective analysisRetrospective studyOutpatient settingHealth servicesDisease controlResultsFrom 2014Same time periodEpidemiologic researchCMHCsPrevention effortsMortalityHealth careServices SurveySuicide ratesAssociationDeath
2019
“Radiotherapy for older women (ROW)”: A risk calculator for women with early-stage breast cancer
Wang SY, Abujarad F, Chen T, Evans SB, Killelea BK, Mougalian SS, Fraenkel L, Gross C. “Radiotherapy for older women (ROW)”: A risk calculator for women with early-stage breast cancer. Journal Of Geriatric Oncology 2019, 11: 850-859. PMID: 31899199, PMCID: PMC7263974, DOI: 10.1016/j.jgo.2019.12.010.Peer-Reviewed Original ResearchConceptsEarly-stage breast cancerRisk calculatorLocal recurrenceBreast cancerOlder womenTumor characteristicsBreast cancer-specific outcomesReceipt of radiotherapyCancer-specific outcomesEarly breast cancerIndividual patient's riskBenefits of radiotherapyAdvisory CommitteeLife expectancyOnline risk calculatorLong-term survivalShared decision makingBenefit of RTOlder adult womenRadiotherapy statusCause mortalityOverall survivalRecurrence reductionFunctional statusPatient riskIncorporating Tumor Characteristics to Maximize 21-Gene Assay Utility: A Cost-Effectiveness Analysis.
Wang SY, Chen T, Dang W, Mougalian SS, Evans SB, Gross CP. Incorporating Tumor Characteristics to Maximize 21-Gene Assay Utility: A Cost-Effectiveness Analysis. Journal Of The National Comprehensive Cancer Network 2019, 17: 39-46. PMID: 30659128, DOI: 10.6004/jnccn.2018.7077.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreast NeoplasmsChemotherapy, AdjuvantClinical Decision-MakingConnecticutCost-Benefit AnalysisDecision Support TechniquesFemaleGene Expression ProfilingGenetic TestingHumansMarkov ChainsMastectomyMiddle AgedModels, StatisticalNeoplasm Recurrence, LocalPrevalencePrognosisQuality-Adjusted Life YearsRisk AssessmentConceptsIncremental cost-effectiveness ratioClinical risk groupsQuality-adjusted life yearsHigh-risk groupLow-risk groupOncotype DXRisk groupsBreast cancerLymph node-negative breast cancerDifferent clinical risk groupsLow-risk breast cancerNode-negative breast cancerIntermediate-risk groupRecurrence score (RS) distributionConnecticut Tumor RegistryER-positive diseaseUS payer perspectivePopulation-based dataCost-effectiveness ratioProbabilistic sensitivity analysesCost-effectiveness analysisODX resultsClinical characteristicsMost patientsPatient age
2018
Ageism Amplifies Cost and Prevalence of Health Conditions
Levy BR, Slade MD, Chang ES, Kannoth S, Wang SY. Ageism Amplifies Cost and Prevalence of Health Conditions. The Gerontologist 2018, 60: 174-181. PMID: 30423119, PMCID: PMC7182003, DOI: 10.1093/geront/gny131.Peer-Reviewed Original Research
2017
Racial and Ethnic Disparities in Oncotype DX Test Receipt in a Statewide Population-Based Study.
Davis BA, Aminawung JA, Abu-Khalaf MM, Evans SB, Su K, Mehta R, Wang SY, Gross CP. Racial and Ethnic Disparities in Oncotype DX Test Receipt in a Statewide Population-Based Study. Journal Of The National Comprehensive Cancer Network 2017, 15: 346-354. PMID: 28275035, DOI: 10.6004/jnccn.2017.0034.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiomarkers, TumorBreast NeoplasmsConnecticutFemaleGene Expression ProfilingGenetic TestingHealth Services AccessibilityHealthcare DisparitiesHumansLymphatic MetastasisMiddle AgedNeoplasm GradingNeoplasm StagingOdds RatioPatient Outcome AssessmentPopulation SurveillanceRegistriesRetrospective StudiesSocioeconomic FactorsYoung AdultConceptsPopulation-based studyOncotype DXODX testingBreast cancerHispanic womenHormone receptor-positive breast cancerReceptor-positive breast cancerRetrospective population-based studyWhite womenRacial disparitiesGEP test resultsBreast cancer careBreast cancer outcomesStudy inclusion criteriaGene expression profiling testsMore white womenClinical characteristicsTest receiptCancer outcomesCancer careInclusion criteriaLogistic analysisEthnic disparitiesStatewide populationWomen
2016
Association between Time since Cancer Diagnosis and Health-Related Quality of Life: A Population-Level Analysis
Wang SY, Hsu SH, Gross CP, Sanft T, Davidoff AJ, Ma X, Yu JB. Association between Time since Cancer Diagnosis and Health-Related Quality of Life: A Population-Level Analysis. Value In Health 2016, 19: 631-638. PMID: 27565280, PMCID: PMC5002308, DOI: 10.1016/j.jval.2016.02.010.Peer-Reviewed Original ResearchConceptsComponent summary scoresSF-6D scoresMental component summary scoresSurvivors of prostateYear of diagnosisPoor-prognosis cancerCancer survivorsSummary scoresCancer diagnosisCervical cancerLower mental component summary scoresLower SF-6D scoresPhysical component summary scoreCancer typesSurvivors of breastHealth-related qualityLevel of HRQoLPatient demographic characteristicsBreast cancer survivorsDecade of diagnosisDemographic characteristicsMost cancer survivorsMedical Expenditure Panel SurveyQuality of lifePoor mental health
2015
Racial Differences in the Use and Outcome of Neoadjuvant Chemotherapy for Breast Cancer: Results From the National Cancer Data Base
Killelea BK, Yang VQ, Wang SY, Hayse B, Mougalian S, Horowitz NR, Chagpar AB, Pusztai L, Lannin DR. Racial Differences in the Use and Outcome of Neoadjuvant Chemotherapy for Breast Cancer: Results From the National Cancer Data Base. Journal Of Clinical Oncology 2015, 33: 4267-4276. PMID: 26598753, DOI: 10.1200/jco.2015.63.7801.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsAsianBiomarkers, TumorBlack or African AmericanBreast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, LobularChemotherapy, AdjuvantComorbidityDatabases, FactualFemaleHispanic or LatinoHumansInsurance CoverageInsurance, HealthMiddle AgedNeoadjuvant TherapyNeoplasm GradingNeoplasm StagingReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneTreatment OutcomeTriple Negative Breast NeoplasmsUnited StatesWhite PeopleConceptsPathologic complete responseNational Cancer Data BaseNeoadjuvant chemotherapyBreast cancerEstrogen receptorWhite womenPositive tumorsAsian womenHuman epidermal growth factor receptor 2HER2-positive breast cancerEpidermal growth factor receptor 2Timing of chemotherapyClinical T stageGrowth factor receptor 2Triple-negative tumorsPatient's zip codeHigh-grade tumorsRacial differencesZip codesFactor receptor 2Chemotherapy useComorbidity indexComplete responseT stageGrade tumors
2012
Health care utilization and health outcomes: a population study of Taiwan
Wang SY, Chen LK, Hsu SH, Wang SC. Health care utilization and health outcomes: a population study of Taiwan. Health Policy And Planning 2012, 27: 590-599. PMID: 22258470, DOI: 10.1093/heapol/czr080.Peer-Reviewed Original ResearchConceptsHealth care utilizationCare utilizationDiabetes mellitusSystem diseasesCerebrovascular diseaseHealth outcomesMortality rateReduced health care utilizationSARS epidemicHealth careCause-specific mortality ratesGenitourinary system diseasesNervous system diseasesNational Health Insurance programRespiratory system diseasesDigestive system diseasesHealth care expendituresHealth Insurance ProgramVascular diseaseMonthly mortality ratesShort-term reductionMellitusInfectious diseasesDiseaseCare expenditures
2010
Ductal Carcinoma In Situ: Risk Factors and Impact of Screening
Virnig BA, Wang SY, Shamilyan T, Kane RL, Tuttle TM. Ductal Carcinoma In Situ: Risk Factors and Impact of Screening. JNCI Monographs 2010, 2010: 113-116. PMID: 20956813, PMCID: PMC5161075, DOI: 10.1093/jncimonographs/lgq024.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge DistributionAgedAged, 80 and overBreast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, Intraductal, NoninfiltratingChemopreventionFemaleHormone Replacement TherapyHumansIncidenceMammographyMass ScreeningMiddle AgedMulticenter Studies as TopicRaloxifene HydrochlorideRandomized Controlled Trials as TopicRisk FactorsTamoxifenYoung AdultConceptsInvasive breast cancerBreast cancerDCIS incidenceDuctal carcinomaRisk factorsIncidence of DCISManagement of DCISRole of chemopreventionPositive family historyUse of mammographyImpact of screeningIncident DCISComedo necrosisMammography useFamily historyDCISHealth OfficeOlder ageIncidenceCancerNational InstituteCarcinomaFurther investigationAgeLiterature reviewIncorporating margin status information in treatment decisions for women with ductal carcinoma in situ: a decision analysis
Wang SY, Kuntz K, Tuttle T, Kane R. Incorporating margin status information in treatment decisions for women with ductal carcinoma in situ: a decision analysis. Breast Cancer Research And Treatment 2010, 124: 393-402. PMID: 20848183, DOI: 10.1007/s10549-010-1166-7.Peer-Reviewed Original ResearchMeSH KeywordsBreast NeoplasmsCarcinoma, Intraductal, NoninfiltratingDecision Support TechniquesFemaleHumansMarkov ChainsMastectomy, SegmentalMiddle AgedNeoplasm Recurrence, LocalPatient PreferencePatient SelectionQuality-Adjusted Life YearsRadiotherapy, AdjuvantRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeConceptsBreast-conserving surgeryQuality-adjusted life yearsRadiation therapyMargin statusDuctal carcinomaRT side effectsDecision-analytic Markov modelOne-way sensitivity analysesImportance of patientsProbabilistic sensitivity analysesDCIS treatmentInvasive recurrenceSalvage mastectomyOptimal treatmentHypothetical cohortTreatment decisionsLifetime horizonSide effectsLife yearsDCISPatientsWomenCarcinomaTreatment